HTL.V - Hamilton Thorne Ltd.

TSXV - TSXV Delayed Price. Currency in CAD
0.80
-0.02 (-2.44%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close0.82
Open0.81
Bid0.80 x 0
Ask0.83 x 0
Day's Range0.80 - 0.81
52 Week Range0.43 - 1.05
Volume10,217
Avg. Volume75,466
Market Cap86.809M
Beta3.52
PE Ratio (TTM)50.00
EPS (TTM)0.02
Earnings DateNov 27, 2017 - Dec 1, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.92
  • GlobeNewswire2 months ago

    Hamilton Thorne Announces 147% Revenue Growth for the Quarter Ended September 30, 2017

    BEVERLY, Mass. and TORONTO, Nov. 21, 2017-- Hamilton Thorne Ltd., a leading global provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies and developmental ...

  • Does Hamilton Thorne Ltd’s (TSXV:HTL) Recent Track Record Look Strong?
    Simply Wall St.2 months ago

    Does Hamilton Thorne Ltd’s (TSXV:HTL) Recent Track Record Look Strong?

    Measuring Hamilton Thorne Ltd’s (TSXV:HTL) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations,Read More...

  • GlobeNewswire2 months ago

    Hamilton Thorne to Announce Q3 2017 Financial Results November 21

    BEVERLY, Mass. and TORONTO, Nov. 15, 2017-- Hamilton Thorne Ltd., a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies and ...

  • Should You Buy Hamilton Thorne Ltd (TSXV:HTL) Now?
    Simply Wall St.3 months ago

    Should You Buy Hamilton Thorne Ltd (TSXV:HTL) Now?

    Hamilton Thorne Ltd (TSXV:HTL), a healthcare equipment and supplies company based in United States, saw significant share price volatility over the past couple of months on the TSXV, rising toRead More...

  • Zacks Small Cap Research5 months ago

    HTL.V: 2017 Second Quarter Revenue Grows By 135%

    On August 23, 2017 Hamilton Thorne (HTL.V) reported financial results for the second quarter of 2017. Revenue for the second quarter increased 135% to $5.6 million as compared to the same period in the prior year which was contributed by the quality control testing services and assay business.  Since Gynemed acquisition was completed in early May 2017, the firm realized partial contribution (two months of revenue) from Gynemed’s product sales during Q2 2017.  Sales were primarily driven by growth in the human clinical market.  Roughly 55% of total sales came from consumables and services.  Revenue was largely inline with our $5.8M estimate.

  • Accesswire7 months ago

    Hamilton Thorne Ltd. to Present at The MicroCap Conference on June 27th in Toronto at the Sheraton Centre Hotel

    TORONTO, ON / ACCESSWIRE / June 8, 2017 / Hamilton Thorne Ltd. (TSX-V: HTL.V, OTC PINK: HTLZF) will be presenting at this year's MicroCap Conference on June 27 th in Toronto. CONFERENCE OVERVIEW AND STRUCTURE ...

  • Zacks Small Cap Research8 months ago

    V.HTL: 62% Revenue Growth in Q1 2017

    On May 25, 2017 Hamilton Thorne (HTL.V) reported financial results for the first quarter of 2017. Revenue for Q1 2017 was $3.3 million led by the contribution from the recently acquired Embryotech business.  Revenue also reflected strong growth in the sales of clinical laser systems and services.

  • Hamilton Thorne And BCSI Announce Distribution Agreement
    PR Newswire8 months ago

    Hamilton Thorne And BCSI Announce Distribution Agreement

    BEVERLY, Mass. and TORONTO, May 23, 2017 /PRNewswire/ -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services, and Blood Cell Storage, Inc. ...

  • Zacks Small Cap Research8 months ago

    HTL.V: Record Revenue for 2016, Accretive Strategic Acquisition of Gynemed; Expect Revenue Boost in 2017.

    On April 28, 2017 Hamilton Thorne (HTL.V) reported financial results for Q4 2016 and annual 2016. The firm had a $5.5 million five-year term loan at 4.25% maturing in September 2021 and a $2.5 million secured line of credit with a US bank which is scheduled to mature in September 2018 and is subject to renewal.  The amended credit agreement will add to its existing credit facility, with two term loans of $4  million at 4.49% and $5.5 million at 4.25% and a $2.5 million line of credit at prime rate (currently 3.75%) which matures two years from the closing date and is renewable annually upon bank approval.  Hamilton Thorne will use the facility to strengthen its working capital position following the acquisition of Gynemed and to position the firm for future growth opportunities.

  • CNW Group9 months ago

    IIROC Trading Resumption - HTL

    IIROC Trading Resumption - HTL

  • PR Newswire9 months ago

    IIROC Trading Resumption - HTL

    VANCOUVER, April 28, 2017 /CNW/ - Trading resumes in: Company: HAMILTON THORNE LTD TSX-Venture Symbol: HTL Resumption (ET): 15:30 IIROC can make a decision to impose a temporary suspension (halt) of trading ...

  • Marketwired9 months ago

    Hamilton Thorne Announces the Acquisition of Gynemed GmbH & Co. KG and Related Financing Transactions

    Hamilton Thorne Ltd. , a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies and developmental biology research markets today announced ...

  • PR Newswire9 months ago

    IIROC Trading Halt - HTL

    VANCOUVER, April 27, 2017 /CNW/ - The following issues have been halted by IIROC: Company: HAMILTON THORNE LTD TSX-Venture Symbol: HTL Reason: At the Request of the Company Pending News Halt Time (ET): ...

  • CNW Group9 months ago

    IIROC Trading Halt - HTL

    IIROC Trading Halt - HTL